Online inquiry

IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15752MR)

This product GTTS-WQ15752MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SEMA4D gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001142287.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10507
UniProt ID Q92854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15752MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8580MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ10629MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ2150MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-518
GTTS-WQ1310MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-700
GTTS-WQ3050MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ267MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ14985MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SHR-1314
GTTS-WQ11700MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW